-
Roche snags postsurgery FDA nod for Alecensa, eyes even broader lung cancer use
19 Apr 2024 20:27 GMT
… selling ALK inhibitor in metastatic lung cancer. The Swiss pharma has … ALK-positive non-small cell lung cancer, Roche’s Genentech unit said … month ahead of the agency’s original target decision … which allows the U.S. agency to collaborate with drug regulators …
-
FDA approves Alecensa for certain patients with ALK-positive lung cancer
19 Apr 2024 19:32 GMT
… -positive non-small cell lung cancer following tumor resection and detection … with early-stage ALK-positive lung cancer,” Levi Garraway, MD, … diagnosed at a younger age, often face recurrence and … diagnosed with early-stage lung cancer undergo testing for ALK …
-
Roche Drug Scores Label Expansion for Earlier Use in Lung Cancer
19 Apr 2024 18:55 GMT
… cancer drug that treats lung cancer with a certain genetic … treatment for non-small cell lung cancer (NSCLC). The latest … England Journal of Medicine.
Lung cancer often metastasizes to the brain … diagnosed at a younger age, often face recurrence and …
-
BNSF Railway attorneys are expected to argue before jurors that the railroad should not be held liable for the lung cancer deaths of two former residents of an asbestos-contaminated Montana town.
19 Apr 2024 16:13 GMT
… be held liable for the lung cancer deaths of two former residents … plaintiffs argued.
The Environmental Protection Agency descended on Libby after the …
-
Q&A: Prompt Diagnosis of Age-Related Macular Degeneration
19 Apr 2024 20:12 GMT
… research?
Dr. Fleckenstein: Given that age-related macular degeneration affects approximately …
Physicians should recognize that older age, genetic factors, and environmental factors … to an increased risk of lung cancer. Additionally, intravitreal anti-VEGF …
-
Roche wins FDA OK for targeted drug in early lung cancer
19 Apr 2024 14:40 GMT
… lung tumors driven by a well-known cancer gene.
On Thursday, the agency … year from lung cancer, and 80% to 85% of lung tumors are of … diagnosed “at a younger age, often face recurrence and … ” program, which allows the agency to begin evaluating an application …
-
Why Lung Cancer Screening Is Not for Everyone
19 Apr 2024 09:30 GMT
… Administration had offered them lung cancer screening.
Of the … Strangely, when deciding about lung cancer screening, the respondents did … RISP) program for early lung cancer diagnosis was launched. Supported … is limited to participants aged 55-75 years. …
-
Young people ageing faster than ever and it could increase risk of early cancers, says doctor
19 Apr 2024 14:07 GMT
… Getty Images)
Young people are ageing faster than ever, and it … examined the biological age - a measurement of age that can … This puts that age group at increasing risk of lung cancer, gastrointestinal cancer … 80,000 young adults aged 20 to 39 are diagnosed …
-
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer
18 Apr 2024 21:57 GMT
… (ALK)-positive non-small cell lung cancer (NSCLC), as detected by an … Medicines and Healthcare products Regulatory Agency. The application reviews are ongoing … at other regulatory agencies involved with Project Orbis.
This …
-
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
18 Apr 2024 21:08 GMT
… including the European Medicines Agency.
About the ALINA study … adverse events.
About lung cancer
According to the American … -85% of all lung cancers. Treating lung cancer early, before it … Information.
About Genentech in lung cancer
Lung cancer is a major area …